TherapeuticsMD shares rise 1.47% and outperform competitors

8 articles · Updated · MarketWatch · May 1

The stock closed at $2.07 as the Nasdaq gained 0.89% to 25,114.44 and the Dow fell 0.31% to 49,499.27.
TherapeuticsMD outperformed AbbVie, whose shares dropped 2.23% to $206.60 during the mixed market session.
Despite Friday's gain, TherapeuticsMD remains 29.83% below its 52-week high of $2.95, and trading volume of 2,724 was well below its 50-day average.

As AbbVie thrives post-patent cliff, can smaller rivals like TherapeuticsMD find a path to survival?

Will TherapeuticsMD's search for a buyer succeed before its legal battle with Mayne Pharma concludes?

Amid a legal battle with Mayne Pharma, can TherapeuticsMD's royalty-only business model survive?